Keytruda fails Phase III study in second-line gastric cancer

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab as second-line treatment missed the primary endpoints in the Phase III KEYNOTE-061 trial in previously treated

Read the full 244 word article

User Sign In